2-bromo-N-(2,2-dimethoxyethyl)-6-fluorobenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-bromo-N-(2,2-dimethoxyethyl)-6-fluorobenzamide
• 化学式: C₁₁H₁₃BrFNO₃
• 分子量: 306.132
• InChiKey: HCGXAWRKDSMRAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-bromo-N-(2,2-dimethoxyethyl)-6-fluorobenzamide 在 甲醇 、 1,1'-双(二苯基膦)二茂铁 、 甲烷磺酸 、 四磷十氧化物 、 palladium diacetate 、 三乙胺 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.17h， 生成 (R/S)-(3-fluoro-2-(oxazol-2-yl)phenyl)(3-methyl-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone
  参考文献：
  名称：

  SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS

  摘要：

  本发明涉及式I的化合物：还描述了制备式I化合物的方法。该发明还涉及包含式I化合物的药物组合物。使用本发明化合物的方法也在本发明的范围内。

  公开号：

  US20160075696A1
• 作为产物：
  描述：

  2-溴-6-氟苯甲酸 、 氨基乙醛缩二甲醇 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.17h， 以82%的产率得到2-bromo-N-(2,2-dimethoxyethyl)-6-fluorobenzamide
  参考文献：
  名称：

  SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS

  摘要：

  本发明涉及式I的化合物：还描述了制备式I化合物的方法。该发明还涉及包含式I化合物的药物组合物。使用本发明化合物的方法也在本发明的范围内。

  公开号：

  US20160075696A1

文献信息

• SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS
  申请人：COATE Heather R.

  公开号：US20160046640A1

  公开（公告）日：2016-02-18

  The present invention is directed to compounds of Formula I: wherein ring A is phenyl, naphihalenyl, pyridyl, quinolinyl, isoquinolinyl, imidazopyridyl, furanyi, tlisazolyl, isoxazolvl, pyrazolyl, imidazothiazolyi, benzimidazolyl, or indazolyi; R 1 is H, alky], aikoxy, hydroxyalkylene, OH, halo, phenyl, triazolyl, oxazolyl, isoxazofyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazmyl, piperazinyl, pyrazolyl, oxadiazolvl, pyrrolidinyl, thiophenyi, morpholinyl, or dialkyiamino; R 2 is H, alkyl, aikoxy, hydroxyalkylene, or halo; Z is NH, N-alkyl, or O; R 5 is pyridyl, pyrimidinyl, pyrazinyl, pyridazmyl, qumazolinyi, quinoxalinyl, pyrazolyl, benzoxazolyl, imidazopyrazinyl, triazolopyrazinyl, optionally substituted with a one or two substituents independently selected from the group consisting of alkyl, aikoxy, or halo; and n is 0 or 1, Methods of making the compounds of Formula 1 are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.

  本发明涉及式I的化合物：其中环A为苯基、萘基、吡啶基、喹啉基、异喹啉基、咪唑吡啉基、呋喃基、噻唑基、异噁唑基、吡唑基、咪唑噻唑基、苯并咪唑基或吲哚基；R1为H、烷基、烷氧基、羟基烷基、OH、卤素、苯基、三唑基、噁唑基、异噁唑基、吡啶基、嘧啶基、吡嗪基、吡啶并嗪基、哌嗪基、吡唑基、噁二唑基、吡咯烷基、噻吩基、吗啉基或二烷氨基；R2为H、烷基、烷氧基、羟基烷基或卤素；Z为NH、N-烷基或O；R5为吡啶基、嘧啶基、吡嗪基、吡啶并嗪基、喹唑啉基、喹喹啉基、吡唑基、苯并噁唑基、咪唑吡嗪基、三唑咪唑基，可选地取代一个或两个独立选择自烷基、烷氧基或卤素的基团；n为0或1，还描述了制备式I化合物的方法。本发明还涉及包含式I化合物的药物组合物。本发明还涉及使用该化合物的方法。
• SUBSTITUTED PIPERIDINE COMPOUNDS AND THEIR USE AS OREXIN RECEPTOR MODULATORS
  申请人：COATE Heather R.

  公开号：US20160046599A1

  公开（公告）日：2016-02-18

  The present invention is directed to compounds of Formula I: wherein X is CR 1 or N; Y is CR 2 or N; Z is NH or O; R 1 is alkoxy, triazolyl, oxazolyl, isoxazolyl, oxadiazolyl, or pyrimidinyl; R 2 is H, alkyl, or halo; R 3 is H, alkyl, alkoxy, halo, triazolyl, oxazolyl, or pyrimidinyl; R 4 is alkyl; R 5 is pyridyl; benzoxazolyl; pyrimidinyl; pyridazinyl; quinoxalinyl; pyrazinyl; or quinazolinyl; wherein the pyridyl; benzoxazolyl; pyrimidinyl; pyridazinyl; quinoxalinyl; pyrazinyl; or quinazolinyl is optionally substituted with one or two substituents independently selected from the group consisting of alkyl, halo, or phenyl; and R 6 is H or alkyl. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods using the compounds of the invention are also within the scope of the invention.

  本发明涉及式I的化合物：其中X为CR1或N; Y为CR2或N; Z为NH或O; R1为烷氧基，三唑基，噁唑基，异噁唑基，噁二唑基或嘧啶基; R2为氢，烷基或卤素; R3为氢，烷基，烷氧基，卤素，三唑基，噁唑基或嘧啶基; R4为烷基; R5为吡啶基; 苯并噁唑基; 嘧啶基; 吡啶二氮杂苯基; 喹喔啉基; 吡嗪基; 或喹唑啉基; 其中吡啶基; 苯并噁唑基; 嘧啶基; 吡啶二氮杂苯基; 喹喔啉基; 吡嗪基; 或喹唑啉基可选地被一个或两个独立选择的取代基取代，所述取代基选自烷基，卤素或苯基; R6为氢或烷基。还描述了制备式I化合物的方法。本发明还涉及包含式I化合物的制药组合物。使用本发明中的化合物的方法也属于本发明的范围。
• Substituted 2-azabicycles and their use as orexin receptor modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US10183953B2

  公开（公告）日：2019-01-22

  The present invention is directed to compounds of Formula I: wherein X is N or CR1; Y is N or CR2; R1 is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; R2 is H, alkyl, alkoxy, or halo; Z is NH or O; R3 is H, alkyl, alkoxy, halo, or triazolyl; R4 is H or alkyl; or R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring; R5 is pyridyl, pyrazinyl, or pyrimidinyl, wherein the pyridyl, pyrazinyl, or pyrimidinyl is optionally substituted with halo or alkyl; and n is 1 or 2. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.

  本发明涉及式 I 的化合物： 其中 X 是 N 或 CR1；Y 是 N 或 CR2；R1 是 H、烷氧基、卤代、三唑基、嘧啶基、噁唑基、异噁唑基、噁二唑基或吡唑基；R2 是 H、烷基、烷氧基或卤代；Z 是 NH 或 O；R3 是 H、烷基、烷氧基、卤代或三唑基；R4 是 H 或烷基；或 R3 和 R4 与它们所连接的原子一起形成 6 元芳基环或 5 元或 6 元杂芳基环； R5 是吡啶基、吡嗪基或嘧啶基，其中吡啶基、吡嗪基或嘧啶基任选被卤素或烷基取代；以及 n 是 1 或 2。本发明还描述了制造式 I 化合物的方法。本发明还涉及包含式 I 化合物的药物组合物。本发明化合物的使用方法也属于本发明的范围。
• Substituted 2-Azabicycles And Their Use As Orexin Receptor Modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US20170204096A1

  公开（公告）日：2017-07-20

  The present invention is directed to compounds of Formula I: wherein X is N or CR 1 ; Y is N or CR 2 ; R 1 is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; R 2 is H, alkyl, alkoxy, or halo; Z is NH or O; R 3 is H, alkyl, alkoxy, halo, or triazolyl; R 4 is H or alkyl; or R 3 and R 4 , together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring; R 5 is pyridyl, pyrazinyl, or pyrimidinyl, wherein the pyridyl, pyrazinyl, or pyrimidinyl is optionally substituted with halo or alkyl; and n is 1 or 2. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.
• US9611277B2
  申请人：——

  公开号：US9611277B2

  公开（公告）日：2017-04-04